122.25
0.80%
0.97
Neurocrine Biosciences Inc stock is traded at $122.25, with a volume of 915.59K.
It is up +0.80% in the last 24 hours and down -18.88% over the past month.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
See More
Previous Close:
$121.28
Open:
$120.19
24h Volume:
915.59K
Relative Volume:
1.03
Market Cap:
$12.34B
Revenue:
$2.12B
Net Income/Loss:
$339.20M
P/E Ratio:
65.73
EPS:
1.86
Net Cash Flow:
$494.60M
1W Performance:
+1.73%
1M Performance:
-18.88%
6M Performance:
-13.79%
1Y Performance:
+6.96%
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-13-23 | Resumed | Citigroup | Neutral |
Dec-12-23 | Initiated | Deutsche Bank | Buy |
Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
Aug-21-23 | Reiterated | Mizuho | Neutral |
Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
Oct-11-22 | Initiated | UBS | Buy |
Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
Jun-06-22 | Resumed | Jefferies | Buy |
Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Sep-23-21 | Resumed | Needham | Hold |
Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
May-18-21 | Resumed | Goldman | Neutral |
May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
Feb-02-21 | Initiated | Raymond James | Outperform |
Sep-30-20 | Initiated | The Benchmark Company | Hold |
Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
Jun-09-20 | Initiated | Wedbush | Outperform |
Mar-06-20 | Initiated | Citigroup | Buy |
Feb-27-20 | Initiated | Barclays | Equal Weight |
Feb-24-20 | Initiated | William Blair | Outperform |
Feb-06-20 | Initiated | Mizuho | Neutral |
Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
Jul-16-19 | Initiated | Oppenheimer | Outperform |
Jun-05-19 | Initiated | Guggenheim | Neutral |
May-21-19 | Initiated | Credit Suisse | Outperform |
Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
Apr-12-19 | Initiated | Evercore ISI | Outperform |
Feb-06-19 | Reiterated | BofA/Merrill | Buy |
Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
Dec-13-18 | Initiated | Goldman | Buy |
Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Dai ichi Life Insurance Company Ltd Has $6.67 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NBIX): Hedge Funds Are Bullish on This Aggressive Growth Stock - Yahoo Finance
Cornercap Investment Counsel Inc. Invests $1.22 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Shifts Focus To New Schizophrenia Treatment After Luvadaxistat Trial Misses Endpoint - Benzinga
Neurocrine’s Phase II schizophrenia trial fails to meet primary endpoint - Clinical Trials Arena
Neurocrine halts luvadaxistat development after trial miss - Investing.com
Neurocrine halts development of schizophrenia drug as trial fails - AOL
Neurocrine ending development of luvadaxistat amid failed study (NASDAQ:NBIX) - Seeking Alpha
Neurocrine Biosciences's Schizophrenia Treatment Misses Endpoint - MarketWatch
Neurocrine Biosciences (NBIX) Provides Update on ERUDITE Phase 2 Data for Luvadaxistat - StreetInsider.com
Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia - StockTitan
Levodopa-induced Dyskinesia Market Growth Anticipated by 2032 - openPR
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Savant Capital LLC - MarketBeat
Analysts Set Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Price Target at $162.20 - MarketBeat
Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia - MSN
Rice Hall James & Associates LLC Reduces Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Huntington's Disease Market Forecasted to Surge in Coming - openPR
Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference - StockTitan
Andra AP fonden Buys 86,900 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) PT Lowered to $160.00 at Barclays - MarketBeat
Decoding 19 Analyst Evaluations For Neurocrine Biosciences - Benzinga
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Holdings Reduced by Los Angeles Capital Management LLC - MarketBeat
Great Lakes Advisors LLC Has $15.32 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Position Raised by Candriam S.C.A. - MarketBeat
When (NBIX) Moves Investors should Listen - Stock Traders Daily
Fiera Capital Corp Raises Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Tardive Dyskinesia (TD) Market Research 2024: Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access - GlobeNewswire Inc.
Nxera wins $35m after Phase II schizophrenia trial success - Clinical Trials Arena
Nxera wins $35m after Phase II schizophrenia trial success - Pharmaceutical Technology
Dollar General, Temu Parent PDD And Super Micro Computer Are Among Top 10 Large Cap Losers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio? - Benzinga
Nxera Pharma to receive $35 million from Neurocrine | Biotechnology | The Pharmaletter - The Pharma Letter
Nxera Pharma Ltd collects clinical US$35m milestone - European Biotechnology News
Van ECK Associates Corp Purchases 3,976 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568 - Yahoo Finance
GraniteShares Advisors LLC Makes New $543,000 Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Holdings Trimmed by Principal Financial Group Inc. - MarketBeat
Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results - MSN
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 1,607,323 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Why Neurocrine Biosciences Stock Was Tumbling This Week - Yahoo Finance
Neurocrine Biosciences (NASDAQ:NBIX) Given New $155.00 Price Target at Cantor Fitzgerald - Defense World
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank - MarketBeat
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock - AOL
Neurocrine Biosciences’ (NBIX) Buy Rating Reiterated at HC Wainwright - Defense World
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock - Yahoo Finance
Cantor Fitzgerald Cuts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $155.00 - MarketBeat
StockWatch: Neurocrine Tumbles as Schizophrenia Data Disappoints - Genetic Engineering & Biotechnology News
Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results - Yahoo Finance
Neurocrine upped to overweight by Piper, sees '568 as still viable (NASDAQ:NBIX) - Seeking Alpha
Neurocrine Biosciences (NASDAQ:NBIX) Earns Buy Rating from HC Wainwright - MarketBeat
Neurocrine’s schizophrenia drug succeeds at phase 2, but dosing questions remain - BioPharma-Reporter.com
Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Reaffirmed by Needham & Company LLC - Defense World
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):